Articular inflammation is a major clinical burden in multiple inflammatory diseases, especially in rheumatoid arthritis. Biological anti-rheumatic drug therapies are expensive and increase the risk of systemic immunosuppression, infections, and malignancies. Here, we report that vagus nerve stimulation controls arthritic joint inflammation by inducing local regulation of innate immune response. Most of the previous studies of neuromodulation focused on vagal regulation of inflammation via the efferent peripheral pathway toward the viscera. Here, we report that vagal stimulation modulates arthritic joint inflammation through a novel ''afferent" pathway mediated by the locus coeruleus (LC) of the central nervous system. Afferent vagal stimulation activates two sympatho-excitatory brain areas: the paraventricular hypothalamic nucleus (PVN) and the LC. The integrity of the LC, but not that of the PVN, is critical for vagal control of arthritic joint inflammation. Afferent vagal stimulation suppresses articular inflammation in the ipsilateral, but not in the contralateral knee to the hemispheric LC lesion. Central stimulation is followed by subsequent activation of joint sympathetic nerve terminals inducing articular norepinephrine release. Selective adrenergic beta-blockers prevent the effects of articular norepinephrine and thereby abrogate vagal control of arthritic joint inflammation. These results reveals a novel neuro-immune brain map with afferent vagal signals controlling side-specific articular inflammation through specific inflammatory-processing brain centers and joint sympathetic innervations.
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Articular inflammation is a major clinical burden in multiple inflammatory diseases, especially in rheumatoid arthritis. Biological anti-rheumatic drug therapies are expensive and increase the risk of systemic immunosuppression, infections, and malignancies. Here, we report that vagus nerve stimulation controls arthritic joint inflammation by inducing local regulation of innate immune response. Most of the previous studies of neuromodulation focused on vagal regulation of inflammation via the efferent peripheral pathway toward the viscera. Here, we report that vagal stimulation modulates arthritic joint inflammation through a novel ''afferent" pathway mediated by the locus coeruleus (LC) of the central nervous system. Afferent vagal stimulation activates two sympatho-excitatory brain areas: the paraventricular hypothalamic nucleus (PVN) and the LC. The integrity of the LC, but not that of the PVN, is critical for vagal control of arthritic joint inflammation. Afferent vagal stimulation suppresses articular inflammation in the ipsilateral, but not in the contralateral knee to the hemispheric LC lesion. Central stimulation is followed by subsequent activation of joint sympathetic nerve terminals inducing articular norepinephrine release. Selective adrenergic beta-blockers prevent the effects of articular norepinephrine and thereby abrogate vagal control of arthritic joint inflammation. These results reveals a novel neuro-immune brain map with afferent vagal signals controlling side-specific articular inflammation through specific inflammatory-processing brain centers and joint sympathetic innervations.
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Introduction
Articular inflammation is the most typical hallmark and major pathological burden in clinical and experimental arthropathies such as rheumatoid arthritis. Articular inflammation causes joint pain, edema, stiffness as well as loss of functionality due to the infiltration of leukocytes into the synovial cavity and the production of inflammatory cytokines such as tumor necrosis factor (TNF) (Firestein, 2003; Sweeney and Firestein, 2004) . Neutrophils are the first type of leukocytes that migrate to the trauma site to eliminate infectious agents and to perform tissue clearance (Firestein, 2003; Sweeney and Firestein, 2004) . However, unregulated neutrophilic activity causes joint deformities and motor disabilities as observed in rheumatoid arthritis (Mantovani et al., 2011; Wright et al., 2014) . Large amounts of neutrophils are found in the synovial fluid of both clinical and experimental arthritic joint inflammation, especially in the early phases (Firestein, 2003; Kolaczkowska and Kubes, 2013; Mohr et al., 1981; Sweeney and Firestein, 2004; Wright et al., 2014) . Currently, there is no cure for rheumatoid arthritis and the best available clinical treatments are based on the use of new biological disease-modifying antirheumatic drugs (bDMARDs) that act mainly by neutralizing TNF and preventing neutrophil activation (Edrees et al., 2005; Inui 
